• YM-155 Hydrochloride: Unraveling Survivin Inhibition in Canc

  2026-06-14

  Explore how YM-155 hydrochloride, a potent survivin inhibitor, is transforming apoptosis inhibitor research with unique mechanistic insights and advanced in vitro assay optimization. Discover how recent systems-biology findings inform practical experimental design.

• Cardiogreen (Indocyanine Green): Applied Workflows in Diagno

  2026-06-13

  Cardiogreen (Indocyanine Green) stands apart as a dual-purpose vascular imaging and therapeutic dye, enabling precise cardiac output measurement and innovative photodynamic therapy for oncology and tissue diagnostics. This article translates high-impact research and experimental protocols into actionable workflows, troubleshooting tips, and practical advances for translational scientists.

• E. coli Uracil-DNA Glycosylase (UDG): Technical Lab Applicat

  2026-06-12

  E. coli Uracil-DNA Glycosylase (UDG) enables targeted removal of uracil from DNA, preventing PCR product contamination and supporting high-fidelity DNA repair workflows. It is not suitable for RNA substrates, oligonucleotides shorter than six bases, or diagnostic use.

• Practical Guide to 740 Y-P: Cell-Permeable PI 3-Kinase Activ

  2026-06-12

  740 Y-P is a potent, cell-permeable PI 3-kinase activator for research applications requiring precise modulation of the PI3K/AKT pathway, including vesicular trafficking, neuronal cell survival, and cancer models. It is best suited for in vitro biochemical and cellular studies where controlled PI3K activation is essential. Use in live animal models or clinical applications is not recommended due to lack of supporting data.

• Next-Gen Mouse Genotyping: Mechanisms, Standards, and Strate

  2026-06-11

  This thought-leadership article explores how optimized lysis buffer formulations—especially those developed by APExBIO—reshape the landscape of rapid mouse genotyping. By blending mechanistic insight with strategic implementation guidance, it empowers translational researchers to connect bench-level protocol choices with high-impact outcomes in genetic research and oncology, referencing recent breakthroughs in autophagy and metastasis signatures for colorectal cancer.

• Macrophage-Targeted Mms6 mRNA-LNPs Enhance SCI Recovery in M

  2026-06-11

  Fu et al. demonstrate that Mms6 mRNA delivered via macrophage-targeted lipid nanoparticles significantly improves locomotor recovery and neural repair after traumatic spinal cord injury in mice. This study highlights the therapeutic potential of mRNA delivery for gene expression modulation in neuroregeneration, providing a rigorous preclinical framework for targeted mRNA therapeutics.

• Scenario-Driven Solutions: Cisplatin (SKU A8321) in Cancer R

  2026-06-10

  Discover how Cisplatin (SKU A8321) streamlines viability, apoptosis, and chemoresistance assays in cancer research. This scenario-driven guide addresses real-world laboratory challenges, integrating recent literature and validated protocols to optimize your workflow with reliable and reproducible results.

• PPM-18: Selective NF-κB/iNOS Inhibition for Sepsis Research

  2026-06-10

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) is a potent, synthetic naphthoquinone derivative that selectively inhibits inducible nitric oxide synthase (iNOS) via NF-κB pathway blockade. Its efficacy in suppressing inflammation, especially in sepsis models, is supported by robust in vitro and in vivo data. PPM-18’s chemical stability and high purity facilitate reproducible results for translational research.

• 25-Hydroxycholesterol Reprograms Macrophage Metabolism via A

  2026-06-09

  Xiao et al. (2024) reveal that 25-hydroxycholesterol (25HC) accumulates in tumor-associated macrophages (TAMs), activating lysosomal AMPK and STAT6 to drive immunosuppressive phenotypes. Targeting the 25HC-CH25H axis enhances anti-tumor immunity and may synergize with checkpoint blockade.

• Scalable EPSC-MSC EV Biomanufacturing for Pulmonary Fibrosis

  2026-06-09

  This study presents a standardized, bioreactor-based platform for producing extracellular vesicles (EVs) from extended pluripotent stem cell-derived mesenchymal stem cells (EPSC-iMSCs). The findings demonstrate high-yield, consistent EV production with verified therapeutic efficacy in a pulmonary fibrosis model, directly addressing longstanding obstacles in EV-based regenerative medicine.

• 17-AAG (Tanespimycin): Strategic Horizons in HSP90 Inhibitio

  2026-06-08

  This article examines the mechanistic depth and translational promise of 17-AAG (Tanespimycin) as a synthetic HSP90 inhibitor, highlighting its disruption of oncogenic signaling, clinical progress, and future potential. Integrating recent findings in regulated cell death, including NINJ1-mediated DAMP release, it offers strategic guidance for translational researchers aiming to advance cancer therapeutics. The discussion bridges molecular insight and clinical application, emphasizing workflow optimization and cross-domain awareness.

• Miltefosine in Leukopenia: Protocols & Dual-Pathway Innovati

  2026-06-08

  Miltefosine stands out as a dual-pathway modulator, uniquely supporting both cancer and hematology research. Recent findings show its unexpected ability to promote neutrophil differentiation via Ras/MEK/ERK activation, enabling new experimental strategies for immune recovery.

• Reliable Src Kinase Assays with PP 1 (Src family tyrosine ki

  2026-06-07

  This article addresses frequent challenges in cell signaling research, providing scenario-driven guidance on using PP 1 (Src family tyrosine kinase inhibitor), SKU A8215, for robust and reproducible Src kinase inhibition. Grounded in quantitative data and real-world laboratory experience, it guides researchers in assay design, protocol optimization, and informed product selection, all while highlighting validated advantages of PP 1 for sensitive biomedical workflows.

• Cisplatin in Cancer Research: Protocols, Resistance & Innova

  2026-06-06

  Cisplatin (CDDP) is a gold-standard chemotherapeutic tool for dissecting apoptosis and DNA repair in oncology models, but maximizing its impact requires workflow precision and troubleshooting. This guide translates cutting-edge resistance-overcoming strategies and actionable parameters into practical lab protocols, leveraging APExBIO’s trusted Cisplatin for reproducible, high-impact results.

• ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR

  2026-06-05

  This study introduces a combinatorial library of biodegradable lipid nanoparticles that leverage high reactive oxygen species (ROS) levels in tumor cells for selective mRNA delivery. The approach achieves increased specificity and efficacy in blocking mutant RAS signaling, with implications for targeted cancer therapeutics and advanced probe-based detection methods.

481 records 10/33 page Previous Next First page 上5页 678910 下5页 Last page